Parenteral iron therapy: A single institution's experience over a 5-year period

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 3, Issue 6, 2005, Pages 791-795

  Laman, Christopher A ^a,b   Silverstein, Scott B ^a,b   Rodgers, George M ^a,b,c  

^a Huntsman Cancer Institute ^*

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Adverse events; Iron dextran; Iron gluconate; Iron sucrose; Parenteral iron

Indexed keywords

DIPHENHYDRAMINE; FERRIC HYDROXIDE SUCROSE; FERROUS GLUCONATE; IRON; IRON DEXTRAN; PARACETAMOL; FERRIC GLUCONATE; FERRIC ION; FERRIC OXIDE, SACCHARATED;

ABDOMINAL PAIN; ANAPHYLAXIS; ANEMIA; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DYSPNEA; FLUSHING; HEADACHE; HUMAN; HYPERTENSION; INJECTION SITE PAIN; IRON DEFICIENCY; IRON THERAPY; MAJOR CLINICAL STUDY; NAUSEA; PREMEDICATION; PRURITUS; SIDE EFFECT; SWELLING; THORAX PAIN; URTICARIA; COMPARATIVE STUDY; FEMALE; GASTROINTESTINAL HEMORRHAGE; INFUSION; IRON DEFICIENCY ANEMIA; IRON METABOLISM DISORDER; KIDNEY DISEASE; MALE; MENORRHAGIA; NEOPLASM; RENDU OSLER WEBER DISEASE; RETROSPECTIVE STUDY; UNITED STATES; VON WILLEBRAND DISEASE;

ACETAMINOPHEN; ANEMIA, IRON-DEFICIENCY; DIPHENHYDRAMINE; FEMALE; FERRIC COMPOUNDS; GASTROINTESTINAL HEMORRHAGE; HUMANS; INFUSIONS, PARENTERAL; IRON METABOLISM DISORDERS; IRON-DEXTRAN COMPLEX; KIDNEY DISEASES; MALE; MENORRHAGIA; NEOPLASMS; PREMEDICATION; RETROSPECTIVE STUDIES; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; UNITED STATES; VON WILLEBRAND DISEASE;

EID: 33644816233     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2005.0047     Document Type: Article

References (7)

1. Fishbane S, Kowalski EA. The comparative safety of intravenous iron dextran, iron saccharate and sodium ferric gluconate. Semin Dial 2000;13:381-384.
2. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301-1307.
3. Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate for increasing response to epoetin in patients with anemia of cancer chemotherapy-results of a multicenter, randomized trial [abstract]. Blood 2004;104 (Part 2):10b.
4. Silverstein SB, Rodgers GM. Parenteral iron therapy options. Am J Hematol 2004;76:74-78.
5. Bailie GR, Clark JA, Lane CE, et al. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 2005;20:1443-1449.
6. Eichbaum Q, Foran S, Dzik S. Is iron gluconate really safer than iron dextran? Blood 2003;101:3756-3757.
7. Chertow GM, Mason PD, Vaage-Nilsen O. On the relative safety of patenteral iron formulations. Nephrol Dial Transplant 2004;19:1571-1575.